Eleven Bio faces cash crunch as lead drug flunks another PhIII

John Carroll FierceBiotech News

Akorn estimates it overstated ’14 financials by $35M

Carly Helfand Last April, Illinois-based Akorn Pharmaceuticals told shareholders it had likely overstated its financial results for the last three quarters of 2014–an announcement ...

Syros raises $40M to get its leukemia drug into Phase II

Damian Garde Syros Pharmaceuticals raised $ 40 million in equity to push forward with its pipeline of genetically targeted drugs, securing the cash it needs to take its top prospect ...

It’s Merck vs. Merck as name confusion, complicated by social media, leads to legal showdown

Eric Palmer Merck has won a legal battle over Merck, which in return says it will file a lawsuit against Merck. It sounds confusing, but confusion is the essence of the legal battle ...

Amgen hits a snag in its plot to challenge AbbVie’s blockbuster Humira

Damian Garde Amgen, at work on a biosimilar of AbbVie's best-selling treatment, got an unfavorable decision from U.S. regulators that could delay the launch of its take on Humira. FierceBiotech ...

Wockhardt spanked again by FDA as agency ticks off violations at new sterile injectables plant

Eric Palmer Wockhardt saw a new plant that will make sterile injectable drugs as its best shot at restoring a U.S. business devastated by FDA product bans. But the Indian ...

Theracos raises $25M to take on Big Pharma in diabetes

Damian Garde Marlborough, MA's Theracos raised $ 25 million to support its work on a safer version of a common treatment for Type 2 diabetes. FierceBiotech News

PTO shuts down Amgen’s Humira IP challenge

Carly Helfand Amgen has hit a potential snag in its quest to bring a biosimilar of AbbVie cash cow Humira to market. Thursday, the U.S. Patent and Trademark Office declined to review ...

Celgene names Mark Alles to CEO position, ending internal contest

Alok Saboo In this week's Chutes and Ladders, Celgene named Mark Alles as CEO, Baxalta CEO Ludwig Hantson will leave following the Shire merger, and MannKind appointed Matthew Pfeffer ...

Biotech rehearses its ‘difficult’ second album at #JPM16

Damian Garde The two most commonly watched indexes of biotech stocks have each fallen more than 35% from their July peaks, battered down by a pervasive sense that the frothy days of ...

Botched drug trial leaves one patient ‘brain-dead,’ 5 hospitalized

Damian Garde A botched Phase I trial has left 6 patients in serious condition with one effectively "brain-dead," according to the French government, which has opened an investigation. FierceBiotech ...

UPDATED: Sarepta shares crash on a harsh FDA review of Duchenne’s drug

John Carroll Sarepta's quest to gain an accelerated approval for eteplirsen was subjected to some harsh scrutiny by regulators at the FDA. And the insiders concluded that much of ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS